ArticleESMO open2020

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.

David Lau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.